Arsenic trioxide

• 

  Subject Areas on Research

  • A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 
  • A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma. 
  • Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). 
  • Arsenic trioxide uptake by human and rat aquaglyceroporins. 
  • Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. 
  • Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. 
  • Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. 
  • Interlaboratory validation of a new assay for DNA-protein crosslinks. 
  • Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. 
  • Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.